cBioPortal for cancer genomics

cBioPortal is a widely used platform for interactive visualization and analysis of large-scale multimodal cancer datasets. It provides cohort exploration tools, such as OncoPrint, mutation “lollipop” plots, survival and enrichment analyses, detailed patient-level views, and integrated variant annotations to support interpretation. The public instance of cBioPortal ( https://www.cbioportal.org ) serves >40,000 unique visitors globally each month. It hosts data from >500 studies, all also available through the cBioPortal Datahub. In 2025, we added 38 new studies (~35,000 samples). We also added Tumor Break Load (TBL) scores across PCAWG, CCLE, and all 32 TCGA Pan-Cancer Atlas studies. More than 99 cBioPortal instances are deployed at institutions and companies worldwide. cBioPortal partners with AACR Project GENIE to provide access to the GENIE cohort in a dedicated instance ( https://genie.cbioportal.org ). Users can explore >268,000 clinically sequenced samples from 20 institutions, as well as GENIE Biopharma Collaborative (BPC) cohorts with detailed clinical annotations, including NSCLC (~2,000 samples), colorectal cancer (~1,500), and breast cancer (~1,200), with more to come. Over the past year, cBioPortal progressed along two complementary directions. First, we introduced a chat-based interface for natural-language data exploration, reflecting ongoing efforts to utilize AI, specifically large language models, to augment traditional query and visualization workflows in cBioPortal. Second, we released several core platform enhancements: 1) we improved the performance for large cohorts by switching the backend database from MySQL to ClickHouse, an OLAP (Online Analytical Processing) database; 2) the Plots tab can now visualize variant allele frequencies, connect multiple samples from the same patient, and has more flexible categorical sorting; 3) variant interpretation has been strengthened through integration of AlphaMissense predictions; 4) we released a redesigned About page highlighting the year's accomplishments and future roadmap. It is worth noting that many of these features were developed using AI-assisted technologies, which are increasingly standard practice in software engineering. cBioPortal is open source ( https://github.com/cBioPortal ) and developed collaboratively by groups at Memorial Sloan Kettering Cancer Center, Dana-Farber Cancer Institute, Children's Hospital of Philadelphia, Princess Margaret Cancer Centre, Bilkent University, SE4BIO, and The Hyve. We welcome contributions from the cancer research community.